文献速递甲状腺疾病

IL-38在甲状腺相关眼病中发挥抗炎和抗纤维化作用

IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究评估IL-38与甲状腺相关眼病(TAO)疾病活动性的关系及其在炎症和纤维化中的作用。研究发现TAO患者循环和眶结缔组织中IL-38水平降低,且与临床活动性评分负相关;体外实验显示IL-38具有抗炎和抗纤维化效应。IL-38可能成为TAO疾病活动性的标志物和治疗靶点。

要点

  • TAO患者循环和眶结缔组织中IL-38水平降低,与临床活动性评分负相关。
  • 体外实验中IL-38表现出抗炎和抗纤维化效应。
  • IL-38可能作为TAO疾病活动性标志物和治疗靶点。

核心结论

  • IL-38在TAO中发挥保护作用,并与TAO发病机制相关。
  • IL-38可能是TAO疾病活动性的有前景标志物和潜在治疗靶点。

研究设计与样本

  • 研究收集了TAO患者和对照者的血液样本和眶结缔组织,并从TAO患者中分离眶成纤维细胞。
  • 采用酶联免疫吸附试验、免疫组化、流式细胞术、免疫荧光、实时定量PCR和Western blot进行分析。

主要发现

  • 与对照者相比,TAO患者循环和眶结缔组织中IL-38水平降低,且与临床活动性评分呈负相关。
  • 体外实验中观察到IL-38具有强效抗炎和抗纤维化作用。
  • IL-38可对抗多种经典通路中star分子的磷酸化。

临床怎么用

  • IL-38水平可能用于评估TAO疾病活动性。
  • IL-38可能作为TAO治疗的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely associated with Graves' disease. IL-38, a novel cytokine in the IL-1 superfamily, has been reported to be involved in the pathogenesis of various autoimmune diseases. OBJECTIVE: We aimed to evaluate the relationship between IL-38 and TAO disease activity and its role in inflammation and fibrosis in TAO. METHODS: Blood samples and orbital connective tissues were collected from TAO patients and controls. Orbital fibroblasts were isolated from patients with TAO. Enzyme-linked immunosorbent assay, immunohistochemistry, flow cytometry, immunofluorescence, quantitative real-time PCR and Western blot analysis were performed. RESULTS: Here, we demonstrated that IL-38 levels decreased in the circulation and orbital connective tissues of patients with TAO compared with the controls, and levels were negatively correlated with the clinical activity score. In vitro, potent anti-inflammatory and antifibrotic effects of IL-38 were observed. Furthermore, we revealed that IL-38 can counteract the phosphorylation of star molecules in multiple classical pathways. CONCLUSION: IL-38 plays a protective role in TAO and is associated with its pathogenesis. Our data suggest that IL-38 may be a promising marker of TAO disease activity and a potential target for TAO therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shi L, Ye H, Huang J, et al. IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab. 2021. PMID: 33693700. doi:10.1210/clinem/dgab154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。